Side Effects of Dextromethorphan
Dextromethorphan is generally safe at therapeutic doses (15-30 mg), but commonly causes central nervous system and autonomic side effects, particularly at supratherapeutic doses, with the most frequent adverse events being ataxia, tachycardia, and neurological symptoms.
Therapeutic Dose Side Effects (15-30 mg)
At recommended doses, dextromethorphan has a favorable safety profile, though side effects can still occur:
- Allergic reactions: The FDA-approved formulation contains sodium metabisulfite, which may cause allergic-type reactions in susceptible individuals 1
- Rare anaphylaxis: Although uncommon, IgE-mediated anaphylaxis has been documented with positive skin testing 2
- Minimal adverse effects: Clinical trials showed no significant difference in adverse events compared to placebo at standard 30 mg doses 3
Overdose and Supratherapeutic Dose Effects
The severity and type of side effects are dose-dependent, with most adverse events occurring after overdose rather than therapeutic use.
Central Nervous System Effects (Most Common)
- Ataxia (most frequent neurological symptom) 4
- Hyperexcitability and increased muscle tone 5
- Dystonia (5.4% of pediatric overdose cases) 4
- Cognitive slowing and motor impairment 6
- Refractory status epilepticus in severe overdose 7
- Reversible cranial nerve reflex loss in massive overdose 7
Autonomic Effects
Dermatologic Effects
- Flushing and/or urticarial rash (18.1% of pediatric cases) 4
Gastrointestinal Effects
- Nausea and vomiting (prominent above 200 mg doses) 6
Psychoactive Effects (Abuse Potential)
At doses ≥100 mg, dextromethorphan exhibits dissociative psychedelic properties:
- Hallucinatory effects beginning at 100 mg 6
- Intensified mystical phenomena at 300-400 mg 6
- Psychological dependency in 46.5% of chronic abusers 8
Critical Clinical Considerations
Pediatric Population
Children under 4 years account for 60% of adverse events, with 69% involving unsupervised self-administration 4. The most common scenario is accidental overdose in young children who access medications without supervision.
Overdose Characteristics
- 78% of adverse events in children followed overdose rather than therapeutic dosing 4
- Mean of 12.49 side effects on first day of abuse, decreasing to 5.57 during first week 8
- Neurological and psychological symptoms predominate in abuse cases 8
Mortality Risk
No deaths occurred in a comprehensive surveillance study of 1,417 single-product dextromethorphan exposures in children, and no pathologic dysrhythmias were identified 4. However, two deaths have been reported in the literature with intentional massive overdose 5.
Pharmacokinetic Factors in Toxicity
In severe overdose, dextromethorphan itself (rather than its metabolite dextrorphan) appears responsible for symptoms, particularly when CYP2D6 metabolism is inhibited by co-ingested medications or genetic factors 7.
Management Implications
The key to preventing adverse events is: